Insider Trading Activity CymaBay Therapeutics Inc. (NASDAQ:CBAY) – Director Bought 5,000 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For CymaBay Therapeutics Inc. (NASDAQ:CBAY)

Robert James Wills , Director of CymaBay Therapeutics Inc. (NASDAQ:CBAY) reportedly Bought 5,000 shares of the company’s stock at an average price of 6.84 for a total transaction amount of $34,200.00 SEC Form

Insider Trading History For CymaBay Therapeutics Inc. (NASDAQ:CBAY)

On 5/15/2015 Charles Mcwherter, VP, bought 2,000 with an average share price of $3.16 per share and the total transaction amounting to $6,320.00.View SEC Filing

On 5/18/2015 Wart Harold Van, CEO, bought 7,500 with an average share price of $3.34 per share and the total transaction amounting to $25,050.00.View SEC Filing

On 5/18/2015 Sujal Shah, CFO, bought 10,000 with an average share price of $3.40 per share and the total transaction amounting to $34,000.00.View SEC Filing

On 7/20/2015 Emster Kurt Von, Director, bought 1,600,000 with an average share price of $2.81 per share and the total transaction amounting to $4,496,000.00.View SEC Filing

On 8/14/2015 Emster Kurt Von, Director, bought 90,000 with an average share price of $2.69 per share and the total transaction amounting to $242,100.00.View SEC Filing

On 9/11/2015 Carl Goldfischer, Director, sold 46,729 with an average share price of $2.74 per share and the total transaction amounting to $128,037.46.View SEC Filing

On 4/4/2016 Sujal Shah, CFO, bought 22,000 with an average share price of $1.39 per share and the total transaction amounting to $30,580.00.View SEC Filing

Analyst Ratings For CymaBay Therapeutics Inc. (NASDAQ:CBAY)
These are 5 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for CymaBay Therapeutics Inc. (NASDAQ:CBAY) is Buy (Score: 3.17) with a consensus target price of $13.80 , a potential (91.67% upside)

Analyst Ratings History For CymaBay Therapeutics Inc. (NASDAQ:CBAY)

On 7/1/2016 Roth Capital Initiated Coverage of rating Buy
On 7/17/2017 HC Wainwright Boost Price Target of rating Buy with a price target of $7.00 to $12.00
On 7/17/2017 Ifs Securities Reiterated Rating Strong-Buy
On 7/20/2017 Citigroup Inc. Reiterated Rating Outperform with a price target of $8.00 to $15.00
On 7/20/2017 Oppenheimer Holdings, Inc. Boost Price Target of rating Outperform with a price target of $8.00 to $15.00
On 7/20/2017 CIBC Reiterated Rating Outperform to Outperform with a price target of $8.00 to $15.00
On 7/25/2017 Piper Jaffray Companies Reiterated Rating Positive to Overweight with a price target of $12.00

Recent Trading Activity for CymaBay Therapeutics Inc. (NASDAQ:CBAY)
Shares of CymaBay Therapeutics Inc. closed the previous trading session at 7.20 up +0.37 5.42% with 947,890 shares trading hands.